Merck looks to ditch the needles with its next-gen oral PCSK9 inhibitor for high cholesterol

After winning approval about six years ago, the first wave of PCSK9 inhibitors largely failed to muster the blockbuster sales analysts had predicted. Now Merck is hoping its oral option will find better success.

The pharma giant unveiled on Monday what it says are the first in-human results for...

Click to view original post